Evaluation of SPN-812 ER Low Dose in Children With ADHD

Trial Profile

Evaluation of SPN-812 ER Low Dose in Children With ADHD

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 May 2018

At a glance

  • Drugs Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 08 May 2018 event According to a Supernus Pharmaceuticals media release, approximately 61% of overall enrollment in the SPN-812 program has been completed. This program consists of four trials: two of which are pediatric trials ( CTP 287730 and CTP 287729 ) and two of which are adolescent trials ( CTP 287727 and CTP 282575 ).
    • 27 Feb 2018 According to a Supernus Pharmaceuticals media release, the Company expects to continue enrollment in this trial through mid-2018 and to have data available by the first quarter of 2019.
    • 06 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Supernus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top